ISSN : 0975-9492
CODEN : IJPSQQ





INTERNATIONAL JOURNAL OF PHARMA SCIENCES AND RESEARCH


Open Access

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information:
verify here.

ABSTRACT

Title : Formulation and In-vitro Evaluation of Orodispersible Tablet
Authors : Rafah Khames Mahal, Dr.Laith H. Samein, Dr. Muyad A.Shehab
Keywords : Nizatidine, Crospovidone, Microcrystalline cellulose, direct compression
Issue Date : April 2015
Abstract :
The formulation researches are oriented towards increasing safety and efficacy of existing drug molecule through a novel concept of drug delivery, one of these is the orodispersible tablet, so the aim of this research is to mask the bitter taste of the nizatidine and to formulate in vitro evaluation of nizatidine orodispersible tablets. Complexation of nizatidine with Kyron T134 showed a better way to mask the bitterness taste of the nizatidine. Nizatidine orodispersible tablet were prepared by direct compression method using sodium starch glycolate, croscarmellose sodium, crospovidone as superdisintegrants. The prepared tablets were evaluated for pre and post compression parameter including Carr’s index, angle of repose, Hausner ratio, hardness, friability, wetting time, in vitro disintegration time, and in vitro drug release. The tablets prepared by direct compression method showed an acceptable flow character. All the formulas exhibited a good mechanical strength. The tablets which prepared by direct compression method showed an acceptable flow character. All the formulas exhibited a good mechanical strength. Crospovidone showed the shortest disintegration time among other superdisintegrants. Moreover the addition of microcrystalline cellulose (Avicel PH102) in a suitable concentration to the formulas containing crospovidone will decrease the disintegration time. The overall results suggested that the prepared formula of nizatidine orodispersible tablet (NF 11) could be promising as a new dosage form for the oral administration.
Page(s) : 689-696
ISSN : 0975-9492
Source : Vol. 6, No.4